Summary sheet
The project concerns investments into research and development (R&D) and related capital expenditure activities in the field of blood analysis, to provide solutions for chronic disease detection and prevention.
The proposed transaction will support further development of the promoter's blood analysis platform, enable to generate scientific evidence of clinical utility of the promoter's risk prediction panel and support achieving reimbursement in Europe.
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorised for the same purpose and would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
The promoter is a private company not operating in the utilities sector and which does not have the status of a contracting authority. Thus, it is not covered by EU Directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. The Bank's services will verify details during the project due diligence.